Pain is the most common reason patients seek medical care and has significant sensory and emotional components. Whilst advances have been made in pain management, few significant ones have occurred, making it harder in recent years to get analgesics to market.
In the current economic climate, this makes it even more imperative for companies to improve their R&D methods so that drugs being put forward for clinical trials have the best chance of success.
Join SMi at the 12th annual Pain Therapeutics conference to discuss the latest advances in drug development practice and analyse recent case studies of where drugs in the clinical stages have succeeded and failed.
Hear key presentations from our expert speaker line-up:
• Chas Bountra, Professor of Translational Medicine, Head, Structural Genomics Centre Oxford University
• Jason Witherington, Head of Chemistry, GlaxoSmithKline
• Jonathan Stewart, Disease Area Head, Neuroscience, Immunology and Pain, Bristol-Myers Squibb
• Philip Kym, Associate Director II Pain Discovery Research, Abbott
• Mark Bowlby, Neurophysiology and Pain Lead, Merck
• Dave Shelton, Senior Director, Pfizer Global Research & Development
Interactive workshops, both held on 23rd May, 8.30am – 12.30pm:
EU Pediatric Requirements in Developing Drugs for Pain Treatment
Led by: Dr Klaus Rose, Managing Director, klausrose Consulting
Utilizing Industry + Academic Alliances in the Development of Pain Treatments
Led by: Professor Fiona Boissonade, Head of Neuroscience Research Group, University of Sheffield
To register, visit www.pain-therapeutics.co.uk or contact Jay Clements at Tel: +44 (0)207 827 6734 or Email: jclements@smi-online.co.uk
